Selling a super cosmeceutical: Contextualising risk in direct-to-consumer advertising of BOTOX® Cosmetic

Health, Risk and Society

Volumn 14, Issue 4, 2012, Pages 385-398

  Mello, Susan ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BOTOX ; Cosmetic; direct to consumer advertising; risk; risk communication; risk perception

Indexed keywords

BOTULINUM TOXIN A; COSMETIC;

ARTICLE; BLADDER DYSFUNCTION; BLEPHAROSPASM; BLURRED VISION; CERVICAL DYSTONIA; CONSUMER; DIPLOPIA; DISEASE SEVERITY; DRUG INDICATION; DRUG MARKETING; DYSPHAGIA; DYSPNEA; ESTHETICS; FLU LIKE SYNDROME; HOARSENESS; HUMAN; HYPERHIDROSIS; INJECTION SITE BLEEDING; INJECTION SITE PAIN; MIGRAINE; MUSCLE WEAKNESS; NECK PAIN; PTOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SELF ACTUALIZATION; SWEATING; UPPER RESPIRATORY TRACT INFECTION; WRINKLE;

EID: 84862104253     PISSN: 13698575     EISSN: 14698331     Source Type: Journal    
DOI: 10.1080/13698575.2012.680951     Document Type: Article

References (78)

1. AARP, 2001. Public attitudes toward aging, beauty, and cosmetic surgery [online]. Available from: http://assets.aarp.org/rgcenter/consume/cosmetic.pdf [Accessed 10 April 2012]
2. Allergan, Inc. 2005. BOTOX® portal [online] Available from: www.botox.com [Accessed 4 February 2009]
3. Allergan, Inc. 2008a. BOTOX® cosmetic injections for frown lines and brow furrows: BOTOX® cosmetic official website [online] Available from: www.BotoxCosmetic.com [Accessed 4 February 2009]
4. Allergan, Inc. 2008b. BOTOX® therapeutic-Cervical dystonia, blepharospasm, strabismus: BOTOX® Therapeutic official website [online] Available from: www.botoxmedical.com [Accessed 4 February 2009]
5. Allergan, Inc. 2008c. Excessive sweating-BOTOX® treatment for hyperhidrosis and excessive underarm perspiration: Official website [online] Available from: www.botoxsevere sweating.com [Accessed 4 February 2009]
6. American Society for Aesthetic Plastic Surgery (ASAPS). 2010. Cosmetic surgery national data bank statistics [online] Available from: http://www.surgery.org/sites/default/files/Stats 2010_1.pdf [Accessed 7 July 2011]
7. American Society of Plastic Surgeons. 2009. 2009 Report of the 2008 procedural statistics-National clearinghouse of plastic surgery statistics [online] Available from: http://www.plasticsurgery.org/News-and-Resources/2009-Statistics.html [Accessed 10 April 2012]
8. Andersson, L. 2002. Cultural gerontology, Westport, CT: Auburn House.
9. Avery, R. J., Eisenberg, M. and Simon, K. I. 2012. Fair balance in direct-to-consumer antidepressant print and television advertising, 1995-2007. Journal of Health Communication, 17 (3): 250-277. doi: 10.1080/10810730.2011.585698
10. Bartky, S. L. 1990. Femininity and domination: Studies in the phenomenology of oppression, New York: Routledge.
11. Bell, R. A., Wilkes, M. S. and Kravitz, R. L. 2000. The educational value of consumer-targeted prescription drug print advertising. Journal of Family Practice, 49(12): 1092-1098.
12. Bordo, S. 1993. Unbearable weight: Feminism, western culture, and the body, Berkeley: University of California Press.
13. Boyles, S. 30 April 2009. "Black box warning for Botox". In WebMD [online] Available from: http://www.webmd.com/skin-problems-and-treatments/news/20090430/black-box-warning-for-botox [Accessed 10 April 2012]
14. Brown, L. 2005. Cosmeceuticals or CosmePSEUDOcals: Examining the FDA's under-sight of celebrity dermatologists in the cosmeceuticals industry, Unpublished Juris Doctor Thesis, Harvard Law School. Available from: http://leda.law.harvard.edu/leda/data/722/brown05.pdf [Accessed 10 April 2012]
15. Calasanti, T. M. and Slevin, K. F. 2006. Age matters: Realigning feminist thinking, New York: Routledge.
16. Carruthers, J. and Carruthers, A. 2007. The evolution of botulinum neurotoxin type A for cosmetic applications. [Review]. Journal of Cosmetic and Laser Therapy, 9(3): 186-192.
17. Carter Singh, G. and Kelly, M. B.H. 2003. Botox: An 'elixir of youth'?. European Journal of Plastic Surgery, 26: 273-274.
18. Chernikoff, L. 20 November 2008. Botox-at age 26? New York doctors weigh in. NY Daily News, [online]. Available from: http://articles.nydailynews.com/2008-11-20/entertainment/17909794_1_botox-wrinkle-reducing-doctor [Accessed 12 April 2012]
19. Compete.com. 2009. Analytic site comparison of botoxcosmetic.com, botoxmedical.com, and botoxsevereweating.com [online] Available from: http://siteanalytics.compete.com/botox cosmetic.com+botoxmedical.com+botoxseveresweating.com/?pid = 43473 [Accessed 17 April 2009]
20. Darwin, C. 1897. The descent of man and selection in relation to sex, New York: D. Appelton.
21. DeLorme, D. E., Huh, J. and Reid, L. N. 2006. Age differences in how consumers behave following exposure to DTC advertising. Health Communication, 20(3): 255-265.
22. Deshpande, A. 2003. Direct-to-consumer advertising and its utility in health care decision making: A consumer perspective. Journal of Health Communication, 9: 499-513.
23. Dooren, J. C. 30 April 2009. FDA strengthens warnings on Allergan's Botox [online] 30 April, Available from: http://english.capital.gr/news.asp?id=726374 [Accessed 12 April 2012]
24. Dowd, M. 2005. Frozen mermaids, scary sirens. The New York Times, 3 March: p. 31, a
25. Etcoff, N. L. 1999. Survival of the prettiest: The science of beauty, (1st ed.), New York: Doubleday.
26. Feder, B.J. 2007. Making Botox both medicine and cosmetic. The New York Times, 23 June: p. 3, a
27. Flint, K. 2000. The victorians and the visual imagination, Cambridge: Cambridge University Press.
28. Foucault, M. 1986. The history of sexuality: The care of the self, Harmondsworth: Penguin.
29. Foucault, M. 1988. "Technologies of the self". In Technologies of the self: A seminar with Michael Foucault, Edited by: Martin, L. H., Gutman, H. and Hutton, P. H. 16-49. London: Tavistock Publications.
30. Furman, F. 1999. "There are no older Venuses: Older women's responses to their aging bodies". In Mother time: Women, aging, and ethics, Edited by: Walker, M. U. 7-22. Lanham, MD: Rowman and Littlefield Publishers.
31. Giddens, A. 1991. Modernity and self-identity: Self and society in the late modern age, Stanford, CA: Stanford University Press.
32. Gill, R. E.A. 2005. Body projects and the regulation of normative masculinity. Body and Society, 11(1): 37-62.
33. Gilleard, C. 2002. "Women aging and body talk". In Cultural gerontology, Edited by: Andersson, L. 139-160. Westport, CT: Auburn House.
34. Gilman, S. 1999. Making the body beautiful: A cultural history of aesthetic surgery, Princeton, NJ: Princeton University Press.
35. Graber, M. A. and Weckman, M. 2002. Pharmaceutical company internet sites as sources of information about antidepressant medications. CNS Drugs, 16(6): 419-423.
36. Haiken, E. 1997. Venus envy: A history of cosmetic surgery, Baltimore, MD: Johns Hopkins Press.
37. Harmon, K. 1 May 2009. FDA acts on risks that Botox effects can spread. Scientific American.Com [online], Available from: http://www.scientificamerican.com/blog/60-sec ond-science/post.cfm?id=fda-acts-on-risks-that-botox-effect-2009-05-01 [Accessed 12 April 2012]
38. Healy, B. 14 January 2007. The Botox balance. US News and World Report [online], Available from: http://health.usnews.com/usnews/health/articles/070114/22healy.htm [Accessed 12 April 2012]
39. Holstein, M. 2006. "On being an aging woman". In Age matters: Realigning feminist thinking, Edited by: Calasanti, T. M. and Slevin, K. F. 313-334. New York: Routledge.
40. Holtz, W. E. 1998. Consumer-directed prescription drug advertising: Effects on public health. Journal of Law and Health, 13(2): 199-218.
41. Huh, J. and Cude, B. J. 2004. Is the information "fair and balanced" in direct-to-consumer prescription drug websites?. Journal of Health Communication, 9(6): 529-540.
42. Hurd Clarke, L. 2011. Facing age: Women growing older in anti-aging culture, Lanham, MD: Rowman & Littlefield Publishers.
43. Hurd Clarke, L., Repta, R. and Griffin, M. 2007. Non-surgical cosmetic procedures: Older women's perceptions and experiences. Journal of Women & Aging, 19(3/4): 69-87.
44. Jeffreys, S. 2005. Beauty and misogyny: Harmful cultural practices in the west, London: Routledge.
45. Jernigan, J. M. and Green, R. 1 September 2004. Building brand value: Payers have spoken, and product managers must construct a value framework for their brands. Pharmaceutical Executive [online], Available from: http://pharmexec.findpharma.com/pharmexec/article/articleDetail.jsp?id=123892&sk=&date=&%0A%09%09%09&pageID=2 [Accessed 12 April 2012]
46. Joyce, K. and Mamo, L. 2006. "Graying the cyborg: New directions in feminist analyses of aging, science, and technology". In Age matters: Realigning feminist thinking, Edited by: Calasanti, T. M. and Slevin, K. F. 353New York: Routledge.
47. Kuehn, B. M. 2008. Studies, reports say botulinum toxins may have effects beyond injection site. Journal of American Medical Association, 299(19): 2261-2263.
48. Kopp, S. W. and Bang, H. K. 2000. Benefit and risk information in prescription drug advertising: Review of empirical studies and marketing implications. Health Market Quarterly, 17(3): 39-56.
49. Macias, W. and Lewis, L. S. 2003. A content analysis of direct-to-consumer prescription drug web sites. Journal of Advertising, 32(4): 43-56.
50. McGuire, S. 5 March 2008. Allergan subpoenaed over Botox promotion materials. Medical Marketing and Media, [online]. Available from: http://www.mmm-online.com/allergan-subpoenaed-over-botox-promotion-materials/article/107663/ [Accessed 12 April 2012]
51. Millsted, R. and Frith, H. 2003. Being large breasted: Women negotiating embodiment. Women's Studies International Forum, 26(5): 455-465.
52. Muise, A. and Desmarais, S. 2010. Women's perceptions and use of "anti-aging" products. Sex Roles, 63: 126-137.
53. MSN.com. 5 May 2009. Popular searches and headlines on MSN: Botox warning [online] Available from: http://a-list.msn.com/default.aspx?cp-searchtext=Botox%20warning [Accessed 17 April 2010]
54. Peiss, K. L. 1998. Hope in a jar: The making of America's beauty culture, New York: Metropolitan Books.
55. Petersen, M. 2003. U.S. warns Botox maker about its ads. The New York Times, 24 June: p. 2, a
56. Raisborough, J. 2007. "Contexts of choice: The risky business of elective cosmetic surgery". In Risks, identities and the everyday, Edited by: Jones, J. S. and Rainsborough, J. 19-36Burlington, VT: Ashgate Publishing Company.
57. Roth, M. S. 1996. Patterns in direct-to-consumer prescription drug print advertising and their public policy implications. Journal of Public Policy & Marketing, 15(1): 63-75.
58. Singer, N. 2009. So Botox isn't just skin deep. The New York Times, 12 April: p. 1, a
59. Solman, G. 23 August 2004. Drug spending soars to record levels. Adweek, 45: 9
60. Thomaselli, R. 2003. Web thrives as DTC platform. Advertising Age, 10 November: p. 21
61. Thomaselli, R. 2005. The side effects of DTC change; drugs makers shift from network to internet, cable ahead of guidelines. Advertising Age, 15 August: p. 1
62. Topaz, M. 2008. Injectable volumetric fillers and botulinum toxin in facial rejuvenation. European Journal of Plastic Surgery, 31: 281-291.
63. US Food and Drug Administration (FDA). 2002a. FDA approves Botox to treat frown lines (Press Release) [online] Available from: http://www.fda.gov/bbs/topics/answers/2002/ans01147.html [Accessed 1 March 2009]
64. US Food and Drug Administration (FDA). 2002b. Is it a cosmetic, a drug, or both? [online] Available from: http://www.cfsan.fda.gov/~dms/cos-218.html [Accessed 1 March 2009]
65. US Food and Drug Administration (FDA). 2002c. Violative advertising and promotional labeling letter botulinum toxin type A, BOTOX cosmetic (Public Letter) [online] Available from: http://www.fda.gov/CDER/biologics/adpromo/botuall090502.htm [Accessed 1 March 2009]
66. US Food and Drug Administration (FDA). 2004. Federal food, drug and cosmetic act [online] Available from: http://www.fda.gov/opacom/laws/fdcact/fdctoc.htm [Accessed 2 March 2009]
67. US Food and Drug Administration (FDA). 2005. Botox fact sheet [online] Available from: http://www.fda.gov/WOMENS/getthefacts/botox.html [Accessed 1 March 2009]
68. US Food and Drug Administration (FDA). 2008a. Early communication about an on-going safety review Botox and Botox cosmetic (botulinum toxin type A) and myobloc (botulinum toxin type B) (Report) [online] Available from: http://www.fda.gov/cder/drug/early_ comm/botulinium_toxins.htm [Accessed 1 March 2009]
69. US Food and Drug Administration (FDA). 2008b. FDA notifies public of adverse reactions linked to Botox use (Press Release) [online] Available from: http://www.fda.gov/bbs/topics/news/2008/new01796.html [Accessed 1 March 2009]
70. US Food and Drug Administration (FDA). 2009. FDA requires boxed warning for all botulinum toxin products (Press Release) [online] Available from: http://www.fda.gov/bbs/topics/NEWS/2009/NEW02005.html [Accessed 1 March 2009]
71. Viscusi, W. K., Magat, W. A. and Huber, J. 1986. Informational regulation of consumer health risks: An empirical evaluation of hazard warnings. RAND Journal of Economics, 17: 351-365.
72. Weise, E. 21 April 2003. The little neurotoxin that could. USA Today,: 1d
73. Wexler, S. Z. April 2009. Brave New Botox. Marie Claire, 16: 174-176.
74. Wilkes, M. S., Bell, R. A. and Kravitz, R. L. 2000. Direct-to-consumer prescription drug advertising: Trends, impact, and implications. Health Affairs, 19(2): 110-128.
75. Wogalter, M. S. 2002. The effects of print format in direct-to-consumer prescription drug advertisements on risk knowledge and preference. Drug Informant Journal, 36: 693-705.
76. Wolf, N. 2002. The beauty myth: How images of beauty are used against women, New York: Perennial.
77. Woloshin, S. 2001. Direct-to-consumer advertisements for prescription drugs: What are Americans being sold?. The Lancet, 358: 1141-1146.
78. Yin, R. K. 2009. Case study research: Design and methods, (4th ed.), Los Angeles, CA: Sage Publications.